Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Online tool aims to empower myeloma patients

NCT ID NCT05673083

Knowledge-focused Sponsor: All4Cure Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests whether a health technology platform called All4Cure can help people with multiple myeloma become more active in managing their own health. Two hundred participants will fill out surveys about their symptoms and how confident they feel in handling their care. No drugs or treatments are being tested—the goal is simply to see if the tool boosts patient engagement.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could show that a simple online tool helps people with multiple myeloma become more involved in their own care, potentially improving their quality of life.
What could go wrong
This is a small pilot study with no drug or treatment being tested. It only measures patient engagement, not disease outcomes, so it may not lead to any direct health improvements.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2023

Expected to finish

Mar 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

This study will enroll up to 200 patients with a diagnosis of multiple myeloma who are receiving treatment at Cancer Specialists of North Florida (CSNF, Florida), Northwest Medical Specialties (NWMS, Washington state), or Highlands Oncology Group (HOG, Arkansas).

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. have a diagnosis of multiple myeloma. 2. are aged 18 years and older. 3. can read and e-consent to participate in the study. 4. can speak English. 5. can complete surveys at pre-specified intervals. 6. have access to a device that would allow for the completion of surveys (including at home, at work, at the oncologist's office or elsewhere). 7. are cared for by a physician who is enrolled in All4Cure. Exclusion Criteria: 1\. Patients will be excluded who are unable to engage with All4Cure or are already participants in All4Cure.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Multiple myeloma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Patient Participation plasma cell myeloma refractory plasma cell neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Multiple myeloma Multiple myeloma in relapse Multiple myeloma refractory Multiple myeloma with failed remission

Contacts and locations

Locations

  • Cancer Specialists of North Florida

    Jacksonville, Florida, 32003, United States

  • Hematology-Oncology Associates of Central New York

    East Syracuse, New York, 13057, United States

  • Highlands Oncology Group

    Fayetteville, Arkansas, 72703, United States

  • Misson Cancer + Blood

    Des Moines, Iowa, 50314, United States

  • Northwest Medical Specialties PLLC

    Tacoma, Washington, 98405, United States

  • Oklahoma Cancer Specialists and Research Institute

    Tulsa, Oklahoma, 74146, United States

  • Oncology Consultants

    Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.